Leinco Technologies

COVID-19 Trace™ IgG MICRO-ELISA Kit

Product Code:
 
LEI-S1500
Product Group:
 
ELISA Kits
Regulatory Status:
 
RUO
Application:
 
Enzyme-Linked Immunosorbent Assay (ELISA)
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-S1500-90Tests90 Tests£472.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Long Description:
Chinese authorities identified an outbreak caused by a novel?or new?coronavirus termed SARS-CoV-2. The virus can cause mild to severe respiratory illness; known as Coronavirus Disease 2019 (COVID-19) formerly called 2019-nCoV.1 SARS-CoV-2 is different from six other previously identified human coronaviruses, including those that have caused previous outbreaks of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The SARS-CoV-2 Spike (S) Protein consists of the S1 and S2 domains.2 The S1 domain contains the receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2) receptors on target cells.2 The SARS-CoV-2 nucleocapsid (N) protein plays a role in transcription, replication, and packaging of the viral RNA genome, while also affecting host cell responses such as cell cycle and translation.3 SARS-CoV-2 is closely related to the SARS virus, which was first identified in 2002-2003.3 In-depth analysis has identified the SARS-CoV-2 RBD as being essential for ACE2 binding.3 Both SARS-CoV and SARS-CoV-2 utilize the ACE2 cellular receptor to gain entry into cells, with SARS-CoV-2 binding with higher affinity.4 Vaccine and therapeutic development are targeting portions of the spike protein, including the RBD portion.5

References

1.) van Dorp L. et al. (2020)Infec Genet Evol 83:104351. Doi:10.1016/j.meegid.2020.104351 2.) Hoffmann et al. (2020) Cell 181: 271?280 3.) Kang, S. et al. (2020) Acta Pharm Sin B. Apr 20. doi: 10.1016/j.apsb.2020.04.009 4.) Wrappet et al. (2020) Science: 2020. 5.) Tai et al. (2020) Cellular & Molecular Immunology 17: 613 ? 620. 6.) Gilchuk, P. et al. (2022) ISCIENCE 103602 Journal Link